<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">19659449</PMID>
      <DateCompleted>
        <Year>2009</Year>
        <Month>10</Month>
        <Day>09</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2009</Year>
        <Month>08</Month>
        <Day>07</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1744-7631</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>13</Volume>
            <Issue>9</Issue>
            <PubDate>
              <Year>2009</Year>
              <Month>Sep</Month>
            </PubDate>
          </JournalIssue>
          <Title>Expert opinion on therapeutic targets</Title>
          <ISOAbbreviation>Expert Opin Ther Targets</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The Hedgehog signalling pathway as a therapeutic target in early breast cancer development.</ArticleTitle>
        <Pagination>
          <StartPage>1095</StartPage>
          <EndPage>1103</EndPage>
          <MedlinePgn>1095-103</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1517/14728220903130612</ELocationID>
        <Abstract>
          <AbstractText>The Hedgehog (Hh) signalling pathway is a highly conserved developmental pathway, which plays critical roles in patterning of the embryo through epithelial to mesenchymal signalling and the maintenance of stem cells in the adult organism. There is increasing evidence that this pathway is dysregulated in many malignancies, including breast cancer. While there has been a significant decrease in mortality from breast cancer, a number of treatment challenges remain, particularly in those tumours which develop resistance to endocrine-based therapy, or which lack expression of hormone or c-erbB2/HER2 receptors. Therapeutic manipulation of the Hh pathway as a potential cancer therapy is attracting great interest, with preclinical studies and clinical trials underway in a range of malignancies. This review highlights important recent developments that affect the potential of the Hh pathway as a novel therapeutic target in early breast cancer.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>O'Toole</LastName>
            <ForeName>Sandra A</ForeName>
            <Initials>SA</Initials>
            <AffiliationInfo>
              <Affiliation>Garvan Institute of Medical Research, Cancer Research Program, Darlinghurst 2010, NSW, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Swarbrick</LastName>
            <ForeName>Alexander</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sutherland</LastName>
            <ForeName>Robert L</ForeName>
            <Initials>RL</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Expert Opin Ther Targets</MedlineTA>
        <NlmUniqueID>101127833</NlmUniqueID>
        <ISSNLinking>1472-8222</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053823">Hedgehog Proteins</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016503" MajorTopicYN="Y">Drug Delivery Systems</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053823" MajorTopicYN="N">Hedgehog Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <NumberOfReferences>62</NumberOfReferences>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2009</Year>
          <Month>8</Month>
          <Day>8</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2009</Year>
          <Month>8</Month>
          <Day>8</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2009</Year>
          <Month>10</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">19659449</ArticleId>
        <ArticleId IdType="doi">10.1517/14728220903130612</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
